FT061

FT061 is an orally active small-molecule antifibrotic agent, chemically described as 3',4'-bis-difluoromethoxycinnamoylanthranilate, developed as an analogue of the anti-allergic drug tranilast to improve antifibrotic efficacy and pharmacokinetics while reducing formation of reactive metabolites.[3][5][11] In preclinical studies, FT061 reduced collagen production and extracellular matrix accumulation in renal mesangial cells, largely via inhibition of transforming growth factor beta (TGF-β)–driven profibrotic signaling, and significantly decreased albuminuria and glomerulosclerosis in rat models of progressive diabetic nephropathy when given orally.[1][3][5][7][11] These data position FT061 as a prototype oral antifibrotic candidate targeting kidney fibrosis and diabetic nephropathy, though clinical development has focused instead on the related analogue FT011.[3]

Other names

3',4'-Bis-difluoromethoxycinnamoylanthranilate